Bellerophon Therapeutics, Inc. announced clearance of its Investigational New Drug (IND) application from the Center for Drug Evaluation of China's National Medical Products Administration (NMPA) to conduct a Phase 3 clinical trial to support the registration of INOpulse for the treatment of fibrotic interstitial lung disease (fILD) in China. The study will utilize Moderate to Vigorous Physical Activity (MVPA) as the primary endpoint and be conducted in collaboration with Bellerophon's regional partner, Baylor BioSciences, a life sciences company dedicated to the development and commercialization of innovative medical products for Greater China.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.051 USD | 0.00% | +2.00% | +37.84% |
May. 02 | North American Morning Briefing : Stock Futures -2- | DJ |
Apr. 25 | North American Morning Briefing : More Tech -2- | DJ |
1st Jan change | Capi. | |
---|---|---|
+37.84% | 624K | |
+20.12% | 126B | |
+25.25% | 119B | |
+25.56% | 27.95B | |
-19.51% | 20.5B | |
-14.36% | 17.12B | |
-15.63% | 16.1B | |
-46.67% | 14.97B | |
+11.89% | 14.84B | |
+57.74% | 14.38B |
- Stock Market
- Equities
- BLPH Stock
- News Bellerophon Therapeutics, Inc.
- Bellerophon Therapeutics, Inc. Receives IND Clearance from China NMPA to Conduct Phase 3 Clinical Trial in China for INOpulse(R) in Fibrotic Interstitial Lung Disease